Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback